The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
- International
Setting the Record Straight on Foreign Trade Barriers
Whether USTR lists foreign trade barriers in its annual catalogue isn’t a matter of aesthetic judgment, it’s often a question of enforcing the law.
By John G. Murphy
- International
Why Restoring America’s Digital Trade Leadership Is Critical
By John G. Murphy - International
The Importance of the U.S.-Brazil Partnership to Advance Priorities in the G20
By Leonardo Abranches
- International
Great Expectations Ahead of Japan’s State Visit
By Charles Freeman - International
How Business Builds Bridges Between the U.S. and Africa
By Kendra Gaither
View this online